Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward
- 24 January 2023
- journal article
- editorial
- Published by Elsevier BV in Value in Health
- Vol. 26 (4), 11-19
- https://doi.org/10.1016/j.jval.2023.01.010
Abstract
No abstract availableFunding Information
- Novartis
This publication has 12 references indexed in Scilit:
- The Real-World Evidence Workstream in EUreccA 2025: How the Task Was AddressedValue in Health, 2023
- Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidanceJournal of Comparative Effectiveness Research, 2021
- Use of real-world evidence in economic assessments of pharmaceuticals in the United StatesJournal of Managed Care & Specialty Pharmacy, 2021
- Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency InitiativeValue in Health, 2020
- Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU—actions for stakeholdersInternational Journal of Technology Assessment in Health Care, 2020
- Real-world evidence use in assessments of cancer drugs by NICEInternational Journal of Technology Assessment in Health Care, 2020
- How to Deal with the Inevitable: Generating Real-World Data and Using Real-World Evidence for HTA Purposes – From Theory to ActionInternational Journal of Technology Assessment in Health Care, 2019
- Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA AgenciesPharmacoEconomics, 2017
- What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder InterviewsValue in Health, 2017
- Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA AgenciesValue in Health, 2017